New psoriasis drug ASC50 completes first trial dosing in the U.S.
June 20, 2025
Source: drugdu
61
According to CSI Smart Finance , Ascletis Pharmaceuticals-B (01672) announced in the morning of June 18 that the board of directors announced that the first batch of healthy subjects have been dosed in the randomized, double-blind, placebo-controlled Phase I clinical trial of ASC50 in the United States. The trial aims to evaluate the safety, tolerability and preliminary efficacy of ASC50 in the treatment of psoriasis (NCT07024602).
ASC50 is an oral small molecule interleukin-17 (IL-17) targeted inhibitor independently developed by Ascletis. IL-17 has been fully biologically validated in various autoimmune and inflammatory diseases such as psoriasis and has mature commercial value.
Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, said: "We are pleased to announce that the first patient has been dosed in the clinical trial of ASC50 for the treatment of psoriasis ahead of schedule, starting the clinical development of this drug candidate. We look forward to obtaining the top-line data of this study in the near future."
https://finance.eastmoney.com/a/202506183433622246.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The Path of the Biotechnology Industry to Net Zero July 7, 2025
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
